Evaluation of the efficacy and tolerance of Soyfem in women in the early menopausal period;Ocena działania i tolerancji preparatu Soyfem u kobiet we wczesnym okresie pomenopauzalnym

Przeglad Menopauzalny

Volumn 5, Issue 3, 2006, Pages 182-190

  Stanosz, Stanisław ^a   Puk, Ewa ^b   Grobelny, Włodzimierz ^a   Stanosz, Małgorzata ^a   Kazikowska, Agnieszka ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Biofarm Sp zoo ^*

Author keywords

Daidzein; Genistein; Isoflavones: genistein; Menopausal period; Oestrogens receptors; Soyfem

Indexed keywords

DAIDZEIN; ESTRADIOL; GENISTEIN; ISOFLAVONE DERIVATIVE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SOYBEAN; STATISTICAL ANALYSIS;

EID: 33746584773     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Nelson H D. Commonly used types of postmenopausal estrogen for treatment of hot flushes. Scientific review. JAMA 2004; 291: 1610-20.
2. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
3. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998; 5: 102-6.
4. Grady D, Herrington D, Bittner V, et al. For the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 49-57.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
6. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy the Million Women Study. Lancet 2003; 362: 419-27.
7. Naftolin F, Schneider H P, Sturdee DW. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333-7.
8. Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 2000; 43: 162-83.
9. Boulet MJ, Oddens BJ, Lehert P, et al. Climacteric and menopause in seven south-east Asian countries. Maturitas 1994; 19: 157-76.
10. Karczmarczuk R. Soja roślina ze wszech miar użyteczna. Wiad Ziel 1999; 61: 6-7.
11. Lu Lin SN, Brady JJ, Nagamani M, et al. Altered kinetics and extent of urinary daidzein and genistein excretion in women during chronic exposure. Nutr Cancer 1996; 26: 289-302.
12. Song TT, Hendrich S, Murphy PA. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem 1999; 47: 1607-10.
13. Setchell KDR. Absorption and metabolism of soy isoflavones from food to dietary supplements and adults to infants. J Nutr 2000; 130: 645S-5S.
14. Albertazzi P, Purdie DW. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas 2002; 42: 173-85.
15. Kuiper GJ, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-beta. Endocrinology 1998; 139: 4252-63.
16. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen antagonists. Mol Farmacol 1998; 54: 105-12.
17. Migliaccio S, Andersen J B. Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporosis Int 2003; 14: 361-8.
18. Stanisz A. Przystepny kurs statystyki w oparciu o program Statistica PC. Wyd StatSoft, Kraków 1998.
19. Kurzer MS. Phytoestrogen supplement use by women. J Nutr 2003; 133: 1983S-6S.
20. Kupperman HS, Blatt MHG, Wiesbader H, et al. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953; 13: 688-703.
21. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68: 1333S-46S.
22. Duncan AM, Phipps WR, Kurzer MS. Phyto-oestrogens. Best Pract Res Clin Endocrinol Metab 2003; 17: 253-71.
23. Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest effects in premenopausal women. J Clin Endocrinol Metab 1999; 84: 192-7.
24. Tomaszewski J. Fitoestrogeny. W: Jakowicki JA. (red). Klimakterium, hormonalna terapia zastepcza. Poradnik Terapeutyczny Bifolium, Lublin 2001.
25. Han KK, Soares JM Jr, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obste Gynecol 2002; 99: 389-94.
26. Faure ED, Chantre P, Mares P. Effects of standardized soy extract on hot flushes: a multicenter, double blind, randomized, placebo-controlled study. Menopause 2002, 9: 329-34.
27. Breziński A, Adlercreutz H, Shaoul R, et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause 1997; 4: 89-94.
28. Sammartino A, Di Carlo C, Mandato AB, et al. Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecol Endocrinol 2003; 17: 45-9.
29. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause 2004; 11: 400-4.
30. Nahas E P, Neto JN, De Luca L, et al. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 2004; 48: 372-80.
31. Kuiper GG, Carlson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
32. Stanosz S. Obwodowe monoaminy biogenne i profil hormonalny u kobiet z nadciśnleniem tetniczym w okresie okołoprzekwitaniowym. Roczniki PAM 1988; 34: 211-46.
33. Silverman AJ, Antunes JL, Ferin M, et al. The distribution of luteinizing hormone releasing (LHRH) in the hypothalamus of the rhesus monkey. Light microscopic studies using immunoperoxidase technique. Endocrinology 1977; 101: 134-42.
34. Heaulme M, Dray F. Noradrenaline and prostaglandin E2 stimulate LH-RH release from rat median eminence through distinct 1-alpha-adrenergic and PGE2 receptors. Neuroendocrinology 1984; 39: 403-7.
35. Wardlaw SL, Wehrenberg WB, Ferin M, et al. Effect of sex steroids on beta-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982; 55: 877-81.